Boothbay Fund Management’s GSK GSK Stock Holding History

Boothbay Fund Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-20,000	Closed	-$768K	–	1980
2025 Q2	$768K	Buy	+20,000	New	+$764K	0.01%	771
2024 Q4	–	Sell	-11,567	Closed	-$473K	–	1666
2024 Q3	$473K	Buy	+11,567	New	+$473K	0.01%	1007
2024 Q2	–	Sell	-238,676	Closed	-$10.2M	–	1665
2024 Q1	$10.2M	Buy	238,676 +25,026	+12%	+$1.03M	0.2%	75
2023 Q4	$7.92M	Sell	213,650 -490,672	-70%	-$17.6M	0.2%	95
2023 Q3	$25.5M	Sell	704,322 -128,186	-15%	-$4.55M	0.61%	14
2023 Q2	$29.7M	Buy	832,508 +23,736	+3%	+$851K	0.65%	11
2023 Q1	$28.8M	Buy	808,772 +368,413	+84%	+$12.9M	0.59%	9
2022 Q4	$15.5M	Buy	440,359 +221,930	+102%	+$7.39M	0.36%	26
2022 Q3	$6.43M	Buy	+218,429	New	+$8.28M	0.16%	116
2022 Q2	–	Sell	-94,850	Closed	-$5.17M	–	2418
2022 Q1	$5.17M	Buy	+94,850	New	+$5.15M	0.12%	203
2021 Q4	–	Sell	-10,198	Closed	-$487K	–	1996
2021 Q3	$487K	Buy	+10,198	New	+$512K	0.01%	1100

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Boothbay Fund Management's GSK Position: Q3 2025 in Review

Boothbay Fund Management sold out of GSK (GSK) in Q3 2025, closing a stake of 20,000 shares — an estimated $768K sold.

Boothbay Fund Management first reported a position in GSK in Q3 2021 and held it in 11 quarters. The position peaked at $29.7M in Q2 2023. 895 funds tracked by Wall St. Rank hold GSK as of Q3 2025.

Boothbay Fund Management reported no remaining GSK position as of Q3 2025 after selling out during the quarter.
Boothbay Fund Management sold 20,000 GSK shares in Q3 2025, an estimated $768K.
Boothbay Fund Management first reported a position in GSK in Q3 2021 and held it in 11 quarters.
Boothbay Fund Management's GSK position peaked at $29.7M in Q2 2023.
895 funds tracked by Wall St. Rank held GSK as of Q3 2025.

Based on Boothbay Fund Management's 13F filing for Q3 2025, filed 14 Nov 2025.